Condition
Ocular Hypertension
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 524 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownMeasuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma SuspectsNCT04401982 · 2026-07-02
RECRUITINGImaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular HypertensionNCT07588152 · 2026-06-05
RECRUITINGDSLT for Reducing Medication in GlaucomaNCT07390890 · 2026-02-10
RECRUITINGBiomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication UseNCT07217678 · 2026-02-09
RECRUITINGEfficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionNCT07335211 · 2026-01-01
RECRUITING[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionNCT07662759 · 2025-12-09
RECRUITING24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension PatientsNCT07325240 · 2025-11-21
RECRUITINGEvaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)NCT07218796 · 2025-10-28
RECRUITINGImplementing AI-based Glaucoma Screening Within Federally Qualified Health CentersNCT06629649 · 2025-10-22
RECRUITINGEvaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)NCT07218783 · 2025-10-15
RECRUITINGIntraocular Pressure Measured by a Novel Sensing Contact Lens Versus TonometryNCT04024293 · 2025-10-01
RECRUITINGAssociation Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on GlaucomaNCT07119580 · 2025-07-08
RECRUITINGSafety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract SurgeryNCT07036510 · 2025-06-12
RECRUITINGLong-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) ShuntNCT06691555 · 2024-11-08
RECRUITINGBioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.NCT05401357 · 2022-06-29
RECRUITINGNanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority TrialNCT05844384 · 2022-03-17
RECRUITINGInflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical ProstaglandinsNCT05039684 · 2021-10-01
RECRUITINGEffect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet CellsNCT04957329 · 2021-09-01
RECRUITINGInvestigation of Neurovascular Coupling in Glaucoma Patients and Healthy SubjectsNCT03870230 · 2017-12-01
RECRUITINGChanges in Intraocular Pressure After Intravitreal InjectionNCT07826286 · 2026-10-01
NOT_YET_RECRUITINGEvaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular HypertensionNCT07641296 · 2026-07-31
NOT_YET_RECRUITINGDorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECHNCT07690397 · 2026-06-10
ACTIVE_NOT_RECRUITINGEfficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle GlaucomaNCT07617532 · 2026-06-01
NOT_YET_RECRUITINGAn Observational Study to Evaluate the ETX-4143 Device in Subjects With Ocular HypertensionNCT06709300 · 2026-01-01
WITHDRAWNGLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) StudyNCT07210216 · 2025-10-01
NOT_YET_RECRUITINGReformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionNCT07082816 · 2025-09-02
COMPLETEDThis Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MINT® Procedure in Open Angle Glaucoma Eyes.NCT07081347 · 2025-06-16
ACTIVE_NOT_RECRUITINGEvaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionNCT06964191 · 2025-05-31
ACTIVE_NOT_RECRUITINGProphylactic Use of Timolol Maleate to Prevent Intraocular Pressure Elevation After Nd:YAG Laser Posterior CapsulotomyNCT07729189 · 2025-03-10
COMPLETED24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP MonitoringNCT06689696 · 2025-02-19
COMPLETEDSelective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma.NCT07756411 · 2025-02-01
COMPLETEDLong-term Outcomes of Glaucoma Surgery in a Real-life Setting: the Agora Registry StudyNCT06829810 · 2025-01-15
COMPLETEDA Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaNCT06666855 · 2024-11-28
ACTIVE_NOT_RECRUITINGLong-term Vascular, Functional and Morphological Changes in Glaucoma and Ocular Hypertensive PatientsNCT06827535 · 2024-11-14
ENROLLING_BY_INVITATIONOpen-Label Study of Safety of H1337 in Healthy VolunteersNCT06572397 · 2024-09-16
COMPLETEDNext Generation RocklatanNCT06441643 · 2024-09-04
COMPLETEDEfficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCTNCT06498440 · 2024-09-01
UNKNOWNEfficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionNCT06394973 · 2024-08-05
COMPLETEDThe A D A G I O StudyNCT06455683 · 2024-06-01
NOT_YET_RECRUITINGLatanoprost Eluting Contact Lens for Treating Glaucoma and Ocular HypertensionNCT04500574 · 2024-04-03
TERMINATEDA Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesNCT06267274 · 2024-04-01
UNKNOWNDirect Selective Laser Trabeculoplasty in Ethnic Chinese PopulationNCT05902871 · 2024-03-11
ACTIVE_NOT_RECRUITINGEVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTSNCT06266351 · 2024-02-12
COMPLETEDA Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular HypertensionNCT06177678 · 2024-02-01
UNKNOWNTravoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular HypertensionNCT06152861 · 2023-11-15
UNKNOWNPh2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressureNCT06144918 · 2023-11-09
COMPLETEDEvaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionNCT06120842 · 2023-10-13
ACTIVE_NOT_RECRUITINGTravoprost Intraocular Implant in Conjunction With Cataract SurgeryNCT06061718 · 2023-09-11
UNKNOWNStudy of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionNCT05913232 · 2023-08-28
COMPLETEDObservational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL CombinationNCT07154810 · 2023-03-16
ACTIVE_NOT_RECRUITINGDorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and SafetyNCT05857267 · 2023-03-07
COMPLETEDSafety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)NCT05495269 · 2022-11-23
COMPLETEDEfficacy of the Nanodropper Device on Intraocular Pressure in Patients With GlaucomaNCT05273385 · 2022-10-10
TERMINATEDSafety and Effectiveness of Drop-free Small Incision Cataract SurgeryNCT05248139 · 2022-10-01
UNKNOWNA Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular HypertensionNCT05456724 · 2022-08-04
UNKNOWNSafety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.NCT05389267 · 2022-07-05
ACTIVE_NOT_RECRUITINGEfficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsNCT05397600 · 2022-06-22
COMPLETEDA Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionNCT04140279 · 2022-05-13
WITHDRAWNEvaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle GlaucomaNCT07154797 · 2022-04-21
COMPLETEDA Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)NCT05335122 · 2022-03-16
COMPLETEDCommon interventions
LatanoprostDRUG17PlaceboDRUG17XalatanDRUG11BimatoprostDRUG10latanoprost 0.005%DRUG10timololDRUG10XalacomDRUG10bimatoprost 0.01%DRUG8Bimatoprost 0.01% ophthalmic solutionDRUG8Latanoprost 0.005% Ophthalmic SolutionDRUG8timolol 0.5%DRUG8latanoprost ophthalmic solution 0.005%DRUG7AR-13324 Ophthalmic Solution 0.02%DRUG6Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensionDRUG6VehicleDRUG6Bimatoprost 0.03%DRUG5Bimatoprost SRDRUG5Latanoprost ophthalmic solution 0.005% (XALATAN®)DRUG5PlaceboOTHER5Selective laser trabeculoplastyPROCEDURE5timolol maleateDRUG5timolol maleate 0.5%DRUG5Timolol Maleate Ophthalmic Solution 0.5% BIDDRUG5Timolol maleate ophthalmic solution, 0.5%DRUG5TravatanDRUG5
Leading sponsors
Alcon Research
98
Allergan
74
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
24
Aerie Pharmaceuticals
19
Mati Therapeutics Inc.
9
Bausch & Lomb Incorporated
8
ForSight Vision5, Inc.
7
Laboratoires Thea
6
Merck Sharp & Dohme LLC
6
Santen Oy
6
Santen Pharmaceutical Co., Ltd.
6
SpyGlass Pharma, Inc.
6
AbbVie
5
Glaukos Corporation
5
Pfizer
5
Trial status mix
COMPLETED402
UNKNOWN41
TERMINATED22
WITHDRAWN20
RECRUITING19
ACTIVE_NOT_RECRUITING12
NOT_YET_RECRUITING5
ENROLLING_BY_INVITATION2
SUSPENDED1
Phase mix
PHASE3139
PHASE2122
PHASE4107
NA55
PHASE149
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.